Financial Performance & Strategy - FY25 revenues reached $1,137.8 million[69] - The company achieved a 5-year revenue CAGR of 34%[17,69] - Adjusted EPS 5-year CAGR was +88%[17] - Organic revenue 5-year CAGR was +24%[17,69] - Adjusted FY25 Free Cash Flow reached $243291 thousand[49,75] - Net leverage was significantly reduced to 24x[49] - The company anticipates approximately $1 billion total Free Cash Flow over the next four years[51] E-commerce & International Expansion - E-commerce as a percentage of net sales has increased +4x from approximately 4% in FY19 to approximately 16% in FY25[33] - International revenue accounts for approximately 16% of Prestige Net Sales in FY25[45] FY26 Outlook - Expected revenue for FY26 is projected to be between $1,100 to $1,115 million[59] - Projected FY26 Non-GAAP Free Cash Flow is $245 million[59,77]

Group 1 - Prestige Consumer Healthcare Inc. will present at the Barclays Global Consumer Staples Conference on September 4, 2025, at 12:45 p.m. ET [1] - Interested parties can access a live webcast of the event on the company's website under the "Investors" section [1] - A replay option will be available on the company's website for those unable to participate in the live webcast [1] Group 2 - Prestige Consumer Healthcare is a leading consumer healthcare products company with sales in the U.S., Canada, Australia, and other international markets [2] - The company's diverse portfolio includes brands such as Monistat®, Summer's Eve®, BC®, Goody's®, Clear Eyes®, TheraTears®, DenTek®, Dramamine®, Fleet®, Chloraseptic®, Luden's®, Compound W®, Little Remedies®, Boudreaux's Butt Paste®, Nix®, Debrox®, Gaviscon®, Hydralyte®, and Fess® [2]

Financial Data and Key Metrics Changes - The company recorded normalized EBITDA of $11,200,000, representing a $13,000,000 improvement compared to the previous corresponding period (PCP) [10] - Group revenue increased by 6% to $261,400,000, with gross profit rising to $137,000,000, up from $126,000,000, resulting in a gross profit margin of 52.4% [19][20] - The group achieved a record number of rolling twelve-month cash actives at 295,800, marking a significant milestone [10] Business Line Data and Key Metrics Changes - In Australia, revenue reached $218,500,000, a 3% increase from the PCP, with gross profit also at a record of $114,500,000, up 2% [11] - The Australian business achieved a statutory segment EBITDA of $30,100,000, reflecting a 12% increase from the PCP [13] - In Canada, net win grew by 26% to $43,000,000, with sports betting net win at $17,000,000, up 11%, and iGaming net win at $26,000,000, increasing by 39% [16][17] Market Data and Key Metrics Changes - The Australian wagering market experienced a material decline, estimated at around 7% for FY 2025, despite PointsBet gaining market share [26][27] - The Canadian market showed strong growth momentum, with a significant increase in cash active clients by 30% to 58,004 [17][18] Company Strategy and Development Direction - PointsBet is focused on enhancing its mass market recreational segments in both Australia and Canada to create a more diversified and sustainable revenue base [10] - The company is actively encouraging reforms in the wagering industry regarding advertising, aiming for a sustainable framework that leverages digital and social media platforms [14][15] Management's Comments on Operating Environment and Future Outlook - Management noted that the Australian market has not grown at a net win level, indicating challenges ahead but expressed hope for a return to growth based on recent positive trends [26][27] - The company anticipates continued market growth tailwinds in the regulated Canadian market, particularly with Alberta expected to go live [18] Other Important Information - PointsBet's board has recommended shareholders accept the MiXi Australia takeover offer, which provides a 50.6% cash premium over the share price prior to the announcement [4][6] - The company paid $115,300,000 in taxes and fees to Australian governments and sports bodies, representing 47.9% of its net win for the year [14] Q&A Session Summary Question: What is the estimated decline in the Australian wagering market for FY 2025? - Management agreed with estimates of around 7% decline, noting that the last quarter showed some positive margins for operators, indicating potential for future growth [26][27] Question: What are the next steps if MiXi exceeds 50.1% ownership? - If MiXi achieves over 50.1% before the offer closes, it will trigger a two-week extension for the offer [28][29]

Financial Data and Key Metrics Changes - The company recorded normalized EBITDA of $11.2 million, a $13 million improvement compared to the previous corresponding period (PCP) [10] - Group revenue increased by 6% to $261.4 million, with gross profit rising to $137 million, up from $126 million, resulting in a gross profit margin of 52.4% [18][19] - The gross profit margin decreased by 0.4 percentage points compared to the PCP [19] Business Line Data and Key Metrics Changes - In Australia, revenue reached a record $218.5 million, up 3% from the PCP, with gross profit also at a record $114.5 million, up 2% [11] - The Australian gross win margin improved by 1.8 percentage points to 13.6%, while the net win margin increased by 1 percentage point to 10.4% [12] - In Canada, net win grew by 26% to $43 million, with sports betting net win at $17 million, up 11%, and iGaming net win at $26 million, up 39% [15][16] Market Data and Key Metrics Changes - The Australian wagering market experienced a material decline, estimated at around 7% for the year, despite PointsBet gaining market share [26] - The Canadian market showed strong turnover growth, maintaining PointsBet's net win market share [15] Company Strategy and Development Direction - PointsBet aims to diversify its revenue base by focusing on mass market recreational segments in both Australia and Canada [10] - The company is actively encouraging reforms in the wagering industry regarding advertising to leverage digital and social media platforms [14] Management Comments on Operating Environment and Future Outlook - Management noted that the Australian market has not grown at a net win level, but there are signs of improvement in the last quarter [26] - The company expects continued market growth tailwinds in the regulated Canadian market [17] Other Important Information - PointsBet paid $115.3 million in taxes and fees to Australian governments and racing bodies, representing 47.9% of its net win for the year [14] - The company had $22.7 million in corporate cash and net assets of $6 million as of June 30, 2025 [21] Q&A Session Summary Question: What is the estimated decline in the Australian wagering market for FY 2025? - Management agreed with estimates of around 7% decline, noting that the last quarter showed some positive margins for operators [26] Question: What are the next steps if MiXi increases above 50.1%? - If MiXi goes through 50.1% before the offer closes, it would trigger a two-week extension for the offer [28][29]

For personal use only FY25 : RESULTS PRESENTATION | August 29 2025 N B C U N I V E R S A L M E D I A P A R T N E R S H I P & F Y 2 0 R E S U L T S P R E S E N T A T I O N │ A U G U S T 2 0 2 0 FY25 RESULTS PRESENTATION AUG 2025 IMPORTANT NOTICE AND DISCLAIMER This document and any oral presentation accompanying it has been prepared in good faith, however, no express or implied representation or warranty is given as to the accuracy or completeness of the information in this document, in any accompanying pres ...

Group 1 - Premium Brands (TSX: PBH:CA) is a Canadian and U.S. food producer, marketer, and distributor that is showing signs of stability in its stock performance after a period of fluctuation [1] - The company is experiencing steady organic growth, indicating a positive trend in its operational performance [1]

Financial Data and Key Metrics Changes - Q1 sales were approximately $250 million, which was below the forecast of $258 million to $260 million, representing a year-over-year decline largely due to supply chain issues in eye care [6][12] - Gross margin expanded by 150 basis points to 56.2%, attributed to ongoing cost savings efforts [8][12] - Diluted EPS was $0.95, up approximately 6% compared to the adjusted prior year, despite the sales miss [9][16] - Free cash flow reached a quarterly record of $78 million, enabling capital deployment to enhance shareholder value [9][17] Business Line Data and Key Metrics Changes - North America segment revenues decreased by 8.4%, while International segment revenues increased by 7.1% year-over-year [13] - The International segment experienced organic sales growth of 7%, driven by broad-based sales growth [14] Market Data and Key Metrics Changes - The company anticipates a full-year revenue of $1.1 billion to $1.115 billion, with organic revenue expected to decline approximately 1.5% to 3% [22] - For Q2, revenues are expected to be approximately $256 million to $259 million, down year-over-year due to supply chain timing and lower retail order patterns [22] Company Strategy and Development Direction - The company announced the acquisition of Pillar Five to secure and expand long-term supply for eye care products, which is expected to improve supply stability in the second half of the year [11][19] - The company maintains confidence in its diverse consumer healthcare portfolio and long-term growth opportunities despite the disappointing start to the year [21] Management Comments on Operating Environment and Future Outlook - Management highlighted heightened business environment uncertainty due to supply chain constraints, high inflation, and geopolitical events [5] - The company expects significant improvement in Clear Eye shipments in the second half of the year, with a focus on recovering lost sales in FY 2027 and beyond [22][29] Other Important Information - The anticipated cost of tariffs for the full year is approximately $5 million, which the company expects to offset through strategic actions [15] - The acquisition of Pillar Five is expected to be funded from cash on hand and will have a minimal impact on the P&L, being approximately neutral to EPS on a normalized basis [19][63] Q&A Session Summary Question: Change in retail order patterns and inventory destocking - Management noted increased order volatility from retailers in July, which is expected to significantly impact Q2 but anticipates a return to normalized order trends in the second half [25][26] Question: Confidence in Clear Eyes supply normalizing - Management expressed confidence in supply normalizing in the back half of the year, with expectations of recovering lost sales in FY 2027 and beyond [29][30] Question: Impact of bringing eye care manufacturing in-house on margins - Management does not expect any meaningful movement in gross margin as a result of the acquisition of Pillar Five, indicating it will be largely neutral to the P&L [37][38] Question: Inventory levels and destocking expectations - Management does not see any meaningful ramp-up of inventory among their largest customers, indicating that inventory levels are not inflated [45][46] Question: Performance of the women's health business - Management remains optimistic about the continued recovery of the Summer's Eve brand, expecting positive performance for the remainder of the year [48] Question: Sustaining international growth - Management is confident in sustaining international growth, expecting a slight softening compared to the first quarter but still in line with long-term growth algorithms [70]

Financial Data and Key Metrics Changes - Q1 sales were approximately $250 million, which was below the forecast of $258 million to $260 million, representing a year-over-year decline largely due to supply chain issues and lower sales in eye care [5][10] - Gross margin expanded by 150 basis points to 56.2%, attributed to cost savings efforts [6][12] - Diluted EPS was $0.95, up approximately 6% from the adjusted prior year, despite the sales miss [7][14] - Free cash flow reached a record $78 million, enabling capital deployment for shareholder value enhancement [7][15] Business Line Data and Key Metrics Changes - North America segment revenues decreased by 8.4%, while International segment revenues increased by 7.1% year-over-year [11][12] - The eye care segment faced significant supply constraints, impacting sales, while other segments like Dramamine and Fleet showed healthy consumption trends [6][12] Market Data and Key Metrics Changes - The International segment experienced organic sales growth of 7%, driven by broad-based sales growth [12] - E-commerce channel saw double-digit year-over-year consumption growth, indicating a long-term trend towards higher online purchasing [12] Company Strategy and Development Direction - The company announced the acquisition of Pillar Five to secure and expand long-term supply for eye care products, which is expected to improve supply stability in the second half of the year [9][17] - The company anticipates revenues for fiscal 2026 to be between $1.1 billion and $1.115 billion, with organic revenue expected to decline approximately 1.5% to 3% [20] Management's Comments on Operating Environment and Future Outlook - Management expressed disappointment in the start of the year but remains confident in the long-term growth opportunities of their consumer healthcare portfolio [19] - The company expects significant improvement in Clear Eye shipments in the second half of the year, despite current supply chain challenges [20][29] Other Important Information - The company maintained a leverage ratio of approximately 2.4 times and repurchased over 400,000 shares in Q1 [7][15] - The anticipated cost of tariffs for the full year is approximately $5 million, which the company expects to offset through strategic actions [13] Q&A Session Summary Question: Change in retail order patterns and inventory destocking - Management noted increased order volatility from retailers in July, disconnected from consistent consumption levels, impacting Q2 significantly [23][24] Question: Confidence in supply normalizing for Clear Eyes - Management expressed confidence in supply normalizing in the back half of the year, with new suppliers and a high-speed line expected to contribute [26][29] Question: Impact of bringing eye care manufacturing in-house on margins - Management indicated no meaningful movement in gross margin as a result of bringing manufacturing in-house, expecting it to be largely neutral to the P&L [36][39] Question: Outlook for cough and cold season - Management maintained the initial guidance for a modest decline in the cough and cold category, too early to tell at this point [42] Question: Inventory levels within segments - Management reported no meaningful ramp-up of inventory, indicating that current order patterns are disconnected from consumption [44] Question: Performance of Summer's Eve brand - Management expressed confidence in the continued positive momentum of the Summer's Eve brand for the remainder of the year [46] Question: International segment growth sustainability - Management expects to sustain international growth, projecting a long-term algorithm of over 5% for the segment [68]

Q1 FY26 Performance - Revenue reached $249.5 million, a 6.6% decrease compared to the previous year[18, 22] - Organic revenue declined by 6.4% year-over-year, primarily due to Clear Eyes supply constraints[17, 24] - Diluted EPS increased by 5.6% to $0.95 compared to the adjusted prior year[11, 17, 18, 22] - Free cash flow was solid at $78 million[11] Financial Metrics - Gross margin improved to 56.2%[11, 22, 24] - EBITDA remained relatively flat at $79.6 million[17, 18, 22] - EBITDA margin increased to 31.9%[22, 24] - A&M expenses accounted for 14.0% of revenue[22, 24] - G&A expenses represented 11.4% of revenue[22, 24] Strategic Initiatives and Outlook - The company entered into an agreement to acquire Pillar5 Pharma for approximately $100 million[11, 25] - The company repurchased approximately 400,000 shares for $35 million[25] - Full-year revenue is projected to be between $1.1 billion and $1.115 billion[28] - Full-year free cash flow is expected to be $245 million or more[28]

Company Performance - Prestige Consumer Healthcare reported quarterly earnings of $0.95 per share, missing the Zacks Consensus Estimate of $1.01 per share, representing an earnings surprise of -5.94% [1] - The company posted revenues of $249.53 million for the quarter ended June 2025, missing the Zacks Consensus Estimate by 4.73%, compared to year-ago revenues of $267.14 million [2] - Over the last four quarters, the company has surpassed consensus EPS estimates two times and topped consensus revenue estimates three times [2] Stock Outlook - Prestige Consumer Healthcare shares have lost about 3.8% since the beginning of the year, while the S&P 500 has gained 7.9% [3] - The company's earnings outlook is crucial for investors, as it includes current consensus earnings expectations for upcoming quarters and any recent changes to these expectations [4] - The current consensus EPS estimate for the coming quarter is $1.19 on revenues of $290.86 million, and for the current fiscal year, it is $4.76 on revenues of $1.15 billion [7] Industry Context - The Medical - Products industry, to which Prestige Consumer Healthcare belongs, is currently in the bottom 37% of over 250 Zacks industries, indicating potential challenges ahead [8] - Empirical research shows a strong correlation between near-term stock movements and trends in earnings estimate revisions, which can impact the stock's performance [5] - The unfavorable trend in estimate revisions prior to the earnings release has resulted in a Zacks Rank 4 (Sell) for the stock, suggesting expected underperformance in the near future [6]